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OBJECTIVES: The study aimed at performing an eco-
nomic analysis in an American setting of the use of tran-
dolapril in postinfarction patients with left ventricular
dysfunction, based on the TRACE trial’s individual 
data. METHODS: The TRACE study was a prospective
placebo-controlled clinical trial designed to determine the
long-term effect of trandolapril in postinfarction patients
with left ventricular dysfunction. From 1992 to 1995,
1749 patients were followed. Our analysis was differen-
tial and was conducted from a Payer and a Medicare Per-
spectives in an American setting. Unit costs were attached
to uses of resources. Mean costs per Diagnosis Related
Groups (DRGs) enabled to value hospital stays for car-
diovascular events. Costs of treatments were obtained by
multiplying the duration of exposure by daily tariffs. The
cost analysis included a longitudinal analysis and multi-
variate regressions to identify cost drivers. The CE analy-
sis consisted in the estimation of the additional cost per
life-saved of treating patients with trandolapril. Uncer-
tainty surrounding the estimate of the CE ratio was taken
into account through a bootstrap analysis. RESULTS:
The mean costs of treatment with trandolapril reached
US$550 in the Payer Perspective. It was over compensated
by ﬁnancial savings in hospitalisations (US$-1308). The
total medical cost was lower (not signiﬁcantly) in the
trandolapril arm, with US$9607 versus US$9953. There
was a trend towards an increase in the cost differential in
favor of trandolapril on the long run. Main cost drivers
were diabetes (OR: 1.88; 95% CI: 1.4,2.5) and nitrate
use (OR: 1.67; 95% CI: 1.3,2.1) at inclusion. Among
5000 resamples of cost and mortality differentials, tran-
dolapril was respectively cost-effective and cost-saving in
33.3% and 66.7% of the cases. The CE analysis provided
similar results in the Medicare perspective. CONCLU-
SIONS: These results obtained in an American setting
could be considered as highly cost effective.
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OBJECTIVES: Anemia is known to affect clinical and
physiological outcomes in heart failure (HF) patients. We
investigate how changing hemoglobin levels inﬂuence
hospital length of stay (LOS) in HF patients across mul-
tiple hospitalizations. Methodological obstacles in apply-
ing 2-stage least squares (2SLS) panel data methods in
administrative data are also discussed. METHODS: A
panel dataset was assembled from claims data represent-
ing 1363 patients with 2 or more HF inpatient stays 
in 21 hospitals nationwide during the 1-year period,
October 1, 2000 through September 30, 2001. LOS is
modeled as a function of hemoglobin level, patient demo-
graphics, procedures performed during hospitalization
and hospital characteristics. To address endogeneity of
hemoglobin and LOS, hemoglobin level is instrumented
for, using indicator variables for hematinic prescriptions
and deﬁciency anemia diagnoses. Encounter data are not
collected at equal intervals. Thus, a key methodological
hurdle is identifying the minimum interval between
encounters meeting assumptions of 2SLS-panel methods.
Validity of model speciﬁcations is explored. Between-
effects and ﬁxed-effects models are developed and com-
pared. RESULTS: For all hemoglobin levels, there is a
slight secular decrease in LOS in the second hospitaliza-
tion during the study period. However, patients experi-
encing the greatest decrease in LOS are those who move
from being anemic in their ﬁrst stay to having normal
hemoglobin levels in their second stay. Between-effects
models indicate that a 1% improvement in hemoglobin
level between patients is associated with a 0.5 % (p <
0.001) decrease in LOS versus the other patients, con-
trolling for other factors. Fixed-effects models show that
a 1% increase in individual hemoglobin level is associ-
ated with a 3.6% (p < 0.001) decrease in LOS for that
individual. CONCLUSIONS: Results suggest the impact
of hemoglobin levels on LOS is greater within individual
patients hospitalized for HF than between individual
patients. Findings must be conﬁrmed in randomized, con-
trolled trials.
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OBJECTIVES: The Heart Outcomes Prevention Evalua-
tion (HOPE) study showed signiﬁcant mortality and mor-
bidity beneﬁts associated with ramipril in high-risk
patients. Cardiac mortality was signiﬁcantly reduced
from 8.1% in placebo to 6.1% in ramipril (RR, 0.74; 
p < 0.001). The objective of this study is to contrast 
multiple cost-effectiveness (CE) scenarios of ramipril in
preventing CV events in high-risk patients. METHODS:
Applying retrospective decision analytic technique, CE
analysis from a payer perspective was conducted using
direct medical costs of clinical events from the literature
and efﬁcacy data from the HOPE study. Expected cost
was estimated using probabilities associated with fatal
and non-fatal myocardial infarction, stroke and other CV
events. CE analysis was conducted under three alternate
scenarios of within-trial analysis based on cost and
outcome during the trial period of 4.5 years, persistent
beneﬁt analysis based on the assumption of therapy being
discontinued beyond trial period and an extended beneﬁt
analysis assuming patients continued on therapy beyond
trial period. Based on life expectancy for a similar cohort
reported in the literature, persistent-beneﬁt of therapy
was assumed for a period of 11.6 years. Extended bene-
ﬁts were obtained by extrapolating within trial efﬁcacy
beyond the study duration. CE analysis was conducted to
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estimate the ratio of incremental expected cost of ramipril
therapy to the incremental life year gained (LYG). All
costs were discounted at 3% per year. RESULTS: Dis-
counted cost for within-trial CE analysis was $2600 for
ramipril compared to $1554 for placebo (incremental
cost, $1046). With a 2% absolute risk reduction in
within-trial cardiac mortality, the incremental cost/LYG
was $11,622. Cost/LYG under the persistent beneﬁt was
$4509. For extended beneﬁt of therapy, cost/LYG was
$4014. Sensitivity analysis ranged from cost/LYG of
$3143 to $12,689. CONCLUSIONS: Ramipril is CE in
preventing CV events in high-risk patients across multi-
ple therapy beneﬁt scenarios.
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OBJECTIVES: To estimate hospital costs and charges
attributable to the development of acute renal insufﬁ-
ciency (ARI) and acute renal failure (ARF) after coronary
artery bypass grafting (CABG). METHODS: A retro-
spective analysis of patients undergoing CABG at Uni-
versity of Pittsburgh Medical Center from June 1998
through May 2002 was conducted. Patients were
matched with respect to severity of illness by APACHE
III scores. A Wilcoxon signed-rank test was used to assess
differences in costs and charges. RESULTS: There were
3741 total patients that resulted in 644 matched pairs.
The mean and median hospital charges among cases were
approximately $221,864 and $158,312 respectively. The
mean and median hospital charges among controls were
approximately $110,868 and $91,738 respectively. Dis-
tribution of the hospital charges were positively skewed
(Shapiro-Wilk test, 0 < 0.001). The difference in median
hospital charges was $66,500 (Wilcoxon signed-rank test,
p < 0.01). The mean and median hospital costs among
cases were $44,180 and $28,901 respectively. The mean
and median hospital costs among controls were $22,471
and $18,038 respectively. The difference in median hos-
pital costs was $10,863 (Wilcoxon signed-rank test, p <
0.01). The mean and median ICU costs among cases were
$35,566 and $21,183 respectively. The mean and median
ICU costs among controls were $17,634 and $13,655
respectively. The difference in median ICU costs was
$7528 (Wilcoxon signed-rank test, p < 0.01). CONCLU-
SIONS: Although patients were matched using APACHE
III scores, a severity of illness scoring system, patients
with ARI/ARF after CABG had signiﬁcantly higher hos-
pital and ICU costs and charges than patients without
ARI/ARF. These differences can be attributed to the devel-
opment of renal complications after CABG.
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Sudden death is one of the two main causes of mortality
in congestive heart failure. Implanted cardioverter deﬁb-
rillator (ICD) is an expensive but highly effective treat-
ment in preventing sudden death. The gain of primary
prophylactic ICD in preventing sudden death in heart
failure has not been clearly established. OBJECTIVE:
Compare the cost-effectiveness of prophylactic ICD with
conventional treatment for preventing sudden death.
METHODS: A lifetime decision model was built. The
perspective is societal. The target population is U.S. HF
patients, aged 60, with NYHA functional Class II and III.
Estimates of cost, utility and probabilities are taken from
literature, clinical experts, CMS fee schedule payment,
and the Bureau of Labor Statistics. In all cases, we assume
that ICD is effective in preventing all sudden death, and
the ICD would be reimplanted at ninth year. In our base
case, we assume that total annual mortality rate is 20%,
of which sudden death accounts for 40%; the utility of
ICD is 10% less during the 1st year after implantation,
and reverts back to pre-implantation level in the 2nd year.
We did a one-way sensitivity analyses on all model para-
meters. RESULTS: the lifetime cost is $117,095 for
patients with prophylactic ICD and $24,709 for patients
with conventional treatment in 2002; the QALYs gained
were 2.9088 and 1.9045 respectively. The CE ratio was
$91,990 per QALY saved. We failed to show that ICD is
cost-effectiveness under any plausible scenario if we use
$50,000 per quality-adjusted-life-year saved as the cut-off
point. CE ratio is sensitive to the utility at the second 
and subsequent years after ICD implantation, and the
proportion of sudden death in all HF-related deaths.
CONCLUSIONS: Using conventional cost effectiveness
benchmarks of $50,000 per life year saved, it is unlikely
that ICD would be cost-effectiveness in preventing sudden
death compared to conventional treatment for heart
failure patients. Future research should focus on patient
utility with and without ICD.
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OBJECTIVES: Previous studies have used Markov
models to predict future CHF hospitalizations based on
